

Rapid Entry into Biologically Relevant α,α -Difluoroalkylphosphonates Bearing Allyl Protection – Deblocking Under Ru(II)/(IV)-Catalysis


Kaushik Panigrahi,[†] Xiang Fei,[†] Masato Kitamura,^{*,‡} David B. Berkowitz^{*,†}

[†] Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588-0304, USA

[‡] Graduate School of Pharmaceutical Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan

dberkowitz1@unl.edu, kitamura@os.rcms.nagoya-u.ac.jp

Supporting Information Placeholder



ABSTRACT: A convenient synthetic route to α,α -difluoroalkylphosphonates is described. Structurally diverse aldehydes are condensed with $\text{LiF}_2\text{CP}(\text{O})(\text{OCH}_2\text{CH}=\text{CH}_2)_2$. The resultant alcohols are captured as the pentafluorophenyl thionocarbonates and efficiently deoxygenated with HSnBu_3 , BEt_3 , O_2 ; then smoothly deblocked with $\text{CpRu}(\text{IV})(\pi\text{-allyl})\text{quinoline-2-carboxylate}$ (1-2 mol %) in methanol as allyl cation scavenger. These mild deprotection conditions provide access to free, α,α -difluoroalkylphosphonates in nearly quantitative yield. This methodology is used to rapidly construct new bis- α,α -difluoroalkyl phosphonate inhibitors of PTPIB (protein phosphotyrosine phosphatase-1B).

Phosphate esters are ubiquitous in Nature, as they provide binding handles and partitioning mechanisms for metabolites, as well as the backbone for nucleic acids and phospholipids.¹ The kinetic stability, yet thermodynamic lability of phosphate esters allows them to serve as on/off-signals for protein regulation and signal transduction and amplification. Since the pioneering work of Blackburn² and McKenna,³ there has been great interest in α,α -difluorinated phosphonates as isopolar mimics of biological phosphates, that are both hydrolytically stable and resistant to phosphatase enzymes. Prior studies on difluorinated phosphonates support the notion of the isopolarity,⁴ reduced pK_a ⁵ and yet added hydrophobicity⁶ of these phosphate mimics.

These postulates have gained significant experimental support, for example, as illustrated in Figure 1, **A** is an effective bisubstrate analogue inhibitor of purine nucleoside phosphorylase (PNP),⁷ a target for gout, and **B** acts as an analogue of phosphoenolpyruvate inactivating of EPSP synthase,⁸ a key target for herbicide development. The β,γ - CF_2 -bridged analogues of dATP (**C**) and ATP (**C'**), act as TS probes for DNA polymerase⁹ and kinase enzymes,¹⁰ respectively. The α,α -difluorinated phosphonate mimics of L-phosphoserine (**D**),¹¹ L-phosphothreonine (**D'**)¹² and L-phosphotyrosine (**E**) serve as useful tools for chemical biology.¹³ These fluorinated phosphonates behave as 'teflon-phosphates' being inert to biological phosphatase enzymes; when site-specifically incorporated in peptides and proteins, they allow for the study of ki-

nase-mediated signal transduction pathways of great interest to drug development.¹⁴ When incorporated into cyclic peptides, the pTyr analogue **F** leads to effective, cell permeable inhibitors of T-cell PTPase.¹⁵ The difluorinated phosphonate mimic of PLP, **F**, has been shown to serve as a useful probe of vitamin B_6 -active sites.¹⁶ Fluorinated phosphonate mimics of dTMP (**G**)¹⁷ and UMP (**G'**)¹⁸ are useful building blocks for phosphonate nucleic acids,¹⁹ an area of burgeoning contemporary interest, particularly for anti-sense applications. Fluorophosphonate analogues of phospho-sugars are useful tools in chemical biology as substrate mimics,²⁰ mechanistic probes²¹ or enzyme inhibitors.²² Glucose 6-phosphate mimic **H** serves both as an alternate substrate for G6PDH²³ and as a mechanistic probe for phosphoglucomutase by NMR.²⁴ Finally, fluorinated phosphonate analogues of phospholipids²⁵ such as LPA (**I**)²⁶ open up new avenues to investigate and modulate phospholipid signaling mechanisms.

Previously, our lab and others have reported convergent routes into the title compounds via $\text{PCF}_2\text{-C}$ bond formation. Such routes include: (i) triflate displacement chemistry with lithio difluoromethylphosphonate anion,²⁷ (ii) condensation of such $(\text{RO})_2\text{P}(\text{O})\text{CF}_2\text{M}$ species with the corresponding aldehydes²⁸ and esters,^{12a, 29} (iii) $\text{Pd}(0)$ -mediated addition of $(\text{RO})_2\text{P}(\text{O})\text{CF}_2\text{I}$ to monosubstituted alkenes followed by reductive deiodination,³⁰ (iv) conjugate addition of $(\text{RO})_2\text{P}(\text{O})\text{CF}_2\text{M}$ reagents to (*E*)-nitroalkenes in the presence of $\text{Ce}(\text{III})$ ³¹ and (v) a series of radical-mediated alkene addition approaches.³² Sev-

eral other elegant routes are specific for generating PCF₂-C(sp²) bonds³³ or directed at allylic systems.³⁴ Also, Piettre and coworkers have recently described a convergent approach into





Figure 1. Bio-Relevant α,α -Difluorinated Phosphonates

the corresponding fluorinated phosphinates.^{19a} However, nearly all of these studies lead to diethyl ester-protected difluoroalkylphosphonates. To date, these esters are typically deprotected with TMSX reagents that combine both nucleophilic and Lewis acidic elements in the reagent itself or when generating the reagent in situ from TMSX and NaBr or KI, for example.³⁵ That said, the TMSX reagent of choice is TMSBr as delineated in a careful comparative study by McKenna and coworkers,³⁶ as is discussed in more detail below.

Early on, our lab reported the synthesis of biologically relevant (α,α -difluoroalkyl)phosphonates bearing allyl ester protecting groups³⁵ by triflate displacement.^{27a} In that study, the fluorinated phosphonate esters thereby obtained were dealylated under Pd(0)-catalysis in the presence of the organic-soluble 2-methylhexanoate anion nucleophile as allyl cation scavenger. The unblocked phosphonates were obtained with modest to excellent (56-91%) yields, depending on the case. While these results were promising, there still were a couple of limitations to the chemistry reported here. On the one hand, while triflate displacement with (RO)₂P(O)CF₂Li provides for convergency, this approach does have a couple of limitations; namely (i) triflates are generally not stable over long periods of time, (ii) molecules containing highly acid sensitive functionalities may not withstand triflate synthesis conditions and (iii) triflates may be incompatible with certain internal functionalities/protecting groups (see the N-para-methoxybenzyl oxazolidinone case in our early efforts to access the pCF₂Ser-phosphonate mimic).^{27c} Therefore, there was a need for new


methodology to synthesize CF₂-phosphonate analogues of biological phosphates under milder conditions, and ideally also with ester deblocking conditions that would be exceptionally gentle to streamline access to these chemical biological tools.

Table 1. P-CF₂-C Bond Formation/Thionocarbonate Capture




We set out to synthesize α,α -difluorinated phosphonates bearing allyl blocking groups via condensation of diallyl lithio(difluoromethyl)phosphonate with a series of aldehydes. Earlier Martin and coworkers had reported the aldehyde condensation route with diethyl lithio(difluoromethyl) phosphonate followed by deoxygenation.^{28b} However, the most significant limitation of the Martin route to (α,α -difluoroalkyl)phosphonate analogues is the need to carry ethyl phosphonate ester protecting groups through the sequence. In order to best mimic a natural phosphorus(V)-based biologically active compound, these ethyl groups need to be removed, typically using TMSX reagents. While Rabinowitz and coworkers had reported the use of TMSCl³⁷ for this purpose early on, the groups of Olah,³⁸ Jung³⁹ and Blackburn⁴⁰ had described the use of TMSI for such purposes, TMSI only performs well at elevated temperature and TMSI is more

Scheme 1. Standard Deoxygenation Conditions Fail



effective for carboxylate ester deprotection than for phosphonate ester deprotection. This latter result was concretely evidenced in an important study by Schmidhauser and McKenna,^{36a} in which it was shown that the TMSBr^{36b, 41} is the TMSX agent of choice for phosphonate ester deprotection.


Table 2. Deoxygenation with Retention of Allyl PGs



While there are many examples of the successful use of TMSBr for the deblocking of diethyl phosphonate protecting groups, particularly for simple phosphonate esters, but also for α,α -difluorinated congeners, we and others have encountered deprotection problems with diethyl/dimethyl/dibutylphosphonate moieties by TMSBr/I when they are appended to certain lactone, pyranose, or amino acid frameworks.⁴² To expand the repertoire of existing deblocking conditions, the corresponding dibenzyl-protected phosphonate reagents were explored, and these proved to be useful in the sugar phosphonate arena.⁴³ However, due to a lack of stability, the $(\text{BnO})_2\text{P}(\text{O})\text{CF}_2\text{Li}$ reagent has not been used extensively for fluorinated phosphonate synthesis. Therefore, we set out to examine a new route into α,α -difluoroalkyl phosphonates that utilizes the $(\text{H}_2\text{C}=\text{CHCH}_2\text{O})_2\text{P}(\text{O})\text{CF}_2\text{Li}$ reagent and that, if successful, would offer medicinal chemists and chemical biologists a streamlined, alternative synthetic entry in this important class of phosphate mimics.

Scheme 2.

Streamlined Route into α,α -Difluorinated Phosphonates




In this new approach, the diallyl (difluoromethyl)phosphonate anion is first added to a target aldehyde at low temperature. The resulting β -hydroxy- α,α -difluoroalkyl phosphonates are then converted to the corresponding arylthionocarbonate esters. While this can be done in situ, if desired, we chose to perform these operations in two steps, as it was felt that the intermediate β -hydroxy- α,α -difluoroalkyl phosphonates might be of real interest for some chemical biology applications, and so these were fully characterized. Unfortunately, in model studies with benzaldehyde, deoxygenation of the aryl thionocarbonate ester so obtained using typical Barton conditions was largely unsuccessful (Scheme 1).⁴⁴ The very low yield of desired product obtained led us to make a crucial modification in the synthetic approach. In order to prevent undesired side reactions, it was discovered that one could lower the reaction temperature from 80 °C to ambient temperature by replacing the usual AIBN initiator with $\text{Et}_3\text{B}/\text{air}$. The modified Barton conditions⁴⁵ were found to be successful. Under these conditions, the allyl phosphonate ester protecting groups are stable to the radical tin chemistry and the pentafluorophenyl thionocarbonate esters are cleanly reduced off.

The overall streamlined entry into these fluorinated phosphonates, featuring these mild deoxygenation conditions

is summarized in Scheme 2. In the first step, the diallyl lithio- α,α -difluoromethylphosphonate anion cleanly adds into a range of aldehydes including those appended to protected carbohydrate, purine and vitamin B₆-cofactor scaffolds. The resultant α,α -difluorinated β -hydroxyphosphonates were derivatized as pentafluorophenyl thionocarbonates. As can be seen from Table 1, the method displays broad substrate scope and provides two-step yields of the corresponding thionocarbonate derivatives that are over 63% (> 80% average per step) for all but one densely functionalized protected guanine system **4f**.


The BEt₃/O₂-initiated radical Bu₃SnH-mediated deoxygenation step proceeds particularly efficiently in this sequence. As can be seen from Table 2, for the model system (**4a** → **5a**) described above, one sees a dramatic improvement in yield (86%) over that obtained under traditional AIBN-initiated deoxygenation conditions at elevated temperature (20%). These findings lead us to hypothesize that at the higher deoxygenation temperature initially employed, the intermediate tributyltin radical reacts with the allyl protecting group centers in competition with Sn-S bond formation, the desired entrée into the deoxygenation reaction manifold. Indeed, the deoxygenation conditions described (ambient temperature, oxygen-triethylborane initiation) are a key cog in the methodology presented herein as they are robustly tolerated across all substrates in our library, giving an average deoxygenation yield of ~80%.

Table 3. Deallylation to the Free α,α -Difluorophosphonates



Finally, as is depicted in Table 3, we have deblocked a set of allyl-protected of α,α -difluorinated phosphonate mimics of biological phosphates using the novel Cp-Ru(II)-2-quinolinecarboxylate catalyst developed in the Kitamura group.⁴⁶ To our knowledge, these are the first examples of the use of this catalyst to provide access to this class of “teflon” phosphate mimics. The deallylation proceeds under exceptionally mild conditions, using the cationic Ru(IV)-PF₆ precatalyst shown, at modest loading (1-2%). In addition, with this catalyst system, addition of an exogenous allyl cation acceptor is unnecessary, since the reaction solvent, MeOH fills this role,

monovalent difluorinated phosphonates



bivalent difluorinated phosphonates




Figure 2. Comparison of Rapidly Assembled Mono- and Bivalent Fluorinated Phosphonate PTP1B Inhibitors

affording methyl allyl ether as a volatile, readily removable byproduct. By using this methodology we have demonstrated a streamlined synthesis of a variety of “teflon” phosphonates in fully deprotected form.

As shown in Table 3, the deallylation reaction provides essentially quantitative conversion with all the selected substrates. This methodology provides a practical route into analogues of several biologically relevant phosphates, such as **6b**, an analogue of pyridoxal phosphate (PLP) of proven utility,¹⁶ at a time when modified PLP analogues are finding expanded use in chemical biology,⁴⁷ and **5e**, an analogue of ribose-5-phosphate that could be used to synthesize non-hydrolysable RNA mimics as discussed.^{17, 19b, 19e, 19g} Heterocycle **5f** is a precursor to potent bisubstrate analogue inhibitors of purine nucleoside phosphorylase^{7a} and **5j** is building block for constructing conjugates of the CF₂-phosphonate mannose-6-phosphate (M6P) mimic.⁴⁸ This phosphatase-inert M6P-surrogate is of great interest as an unnatural ligand for the insulin-like growth factor-II receptor (IGFIR). Polyvalent versions of such ligands may promote the dimerization of this receptor and thereby stimulate internalization of circulating IGF-II growth factor, a potential approach to cancer therapy currently under investigation.⁴⁹




Figure 3. Inhibitor 6h Docked in the PTP1B Active Site

Finally, we have rapidly constructed a set of α,α -difluorinated *mono*- and *bis*-phosphonates (**6d**, **6i** and **6g**, **6h**) to demonstrate how this chemistry can be used to assemble targeted libraries, here a set of protein tyrosine phosphatase-1B

inhibitor candidates. PTP1B is a high value potential therapeutic target for type II diabetes.^{14-15, 50} In fact, for such rapidly assembled scaffolds, significant inhibition was observed in the mid-micromolar range with **6h**, in particular. These results highlight the advantage of the *bis*-phosphonates over their monomeric congeners (Figure 2) in binding to PTP1B.

A docked structure of **6h**, bound to the PTP1B active site (from pdb 2B07)⁵¹ is presented in Figure 3 (AutodockVina;⁵² best of 25 poses shown). Each difluorinated phosphonate group is seen to engage in favorable electrostatic/H-bonding interactions with R24 and K120, with each arene ring of the inhibitor available for edge-to-face π - π interactions with F182 and Y46, respectively. Thus inhibitor **6h** is expected to be a useful tool for chemical biology; it is a potential lead scaffold for PTP inhibitor development to facilitate the study of signal transduction via protein (de)phosphorylation.^{13a}

In conclusion, a practical route for the synthesis of α,α -difluoroalkyl)phosphonates bearing allyl ester protection has been established, by exploiting the favorable low temperature condensation of the $(\text{H}_2\text{C}=\text{CHCH}_2\text{O})_2\text{P}(\text{O})\text{CF}_2\text{Li}$ reagent with a set of functionalized aldehydes appended to diverse biologically relevant scaffolds. A modified Barton deoxygenation is then employed, compatible with the presence of allyl phosphonate ester functionality. Fluorinated phosphonate deprotection is achieved under exceptionally mild conditions with the Ru (II)-catalyst pioneered in the Kitamura lab. The new method has been applied to the synthesis of CF_2 -phosphonate mimics of PLP (vitamin B₆), D-mannopyranosyl and D-ribofuranosyl phosphates and an established purine-based phosphonate scaffold for PNP inhibition. Finally, this chemistry has been deployed in a parallel, bidirectional fashion using aromatic *bis*-aldehyde substrates to provide rapid access to

simple *bis*- α,α -difluoromethylene phosphonates that display mid-micromolar inhibitory potency against PTP1B. Indeed, PTP inhibitor **6h** provides an attractive and readily accessible scaffold from which to potentially build out specificity and enhanced affinity across the PTP family of signal-transducing enzymes.

ASSOCIATED CONTENT

Supporting Information

Detailed experimental procedures (synthesis and enzyme kinetics assays) and characterization data (¹H, ¹³C, ¹⁹F and ³¹P NMR spectra)-182 pages. This material is available free of charge via the Internet: <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: dberkowitz1@unl.edu; kitamura@os.rcms.nagoya-u.ac.jp

ACKNOWLEDGMENT

This work was supported in part by NSF CHE-1500076 and CHE-1800574. These studies were initiated by a JSPS Fellowship to DBB that brought DBB and MK together and were facilitated by the IR/D program for DBB's appointment at the NSF. The authors thank Martin Osinde and Ranjeet Dhokale (both of the University of Nebraska) for assistance with modeling, and data analysis, respectively; NIH (SIG-1-510-RR-06307), NSF (CHE-0091975 and MRI-0079750) for NMR instrumentation and NIH (RR016544) for facilities.

(10) Ni, F.; Kung, A.; Duan, Y.; Shah, V.; Amador, C. D.; Guo, M.; Fan, X.; Chen, L.; Chen, Y.; McKenna, C. E.; Zhang, C., *J. Am. Chem. Soc.* **2017**, *139*, 7701-7704.

(11) (a) Tarrant, M. K.; Rho, H.-S.; Xie, Z.; Jiang, Y. L.; Gross, C.; Culhane, J. C.; Yan, G.; Qian, J.; Ichikawa, Y.; Matsuoka, T.; Zachara, N.; Etzkorn, F. A.; Hart, G. W.; Jeong, J. S.; Blackshaw, S.; Zhu, H.; Cole, P. A., *Nat. Chem. Biol.* **2012**, *8*, 262-269; (b) Panigrahi, K.; Eggen, M.; Maeng, J.-H.; Shen, Q.; Berkowitz, D. B., *Chem. Biol.* **2009**, *16*, 928-936; (c) Zheng, W.; Schwarzer, D.; LeBeau, A.; Weller, J. L.; Klein, D. C.; Cole, P. A., *J. Biol. Chem.* **2005**, *280*, 10462-10467; (d) Higashimoto, Y.; Saito, S. i.; Tong, X.-H.; Hong, A.; Sakaguchi, K.; Appella, E.; Anderson, C. W., *J. Biol. Chem.* **2000**, *275*, 23199-23203.

(12) (a) Berkowitz, D. B.; Eggen, M.; Shen, Q.; Shoemaker, R. K., *J. Org. Chem.* **1996**, *61*, 4666-4675; b Chen, H.-X.; Kang, J.; Chang, R.; Zhang, Y.-L.; Duan, H.-Z.; Li, Y.-M.; Chen, Y.-X., *Org. Lett.* **2018**, *20*, 3278-3281.

(13) (a) Lu, C. H. S.; Liu, K.; Tan, L. P.; Yao, S. Q., *Chem. - Eur. J.* **2012**, *18*, 28-39; (b) Yun, S.-M.; Moulaei, T.; Lim, D.; Bang, J. K.; Park, J.-E.; Shenoy, S. R.; Liu, F.; Kang, Y. H.; Liao, C.; Soung, N.-K.; Lee, S.; Yoon, D.-Y.; Lim, Y.; Lee, D.-H.; Otaka, A.; Appella, E.; McMahon, J. B.; Nicklaus, M. C.; Burke, T. R., Jr.; Yaffe, M. B.; Wlodawer, A.; Lee, K. S., *Nat. Struct. Mol. Biol.* **2009**, *16*, 876-882.

(14) Groves, M. R.; Yao, Z.-J.; Roller, P. P.; Burke, T. R., Jr.; Barford, D., *Biochemistry* **1998**, *37*, 17773-17783.

(15) Liao, H.; Pei, D., *Org. Biomol. Chem.* **2017**, *15*, 9595-9598.

(16) Stirtan, W. G.; Withers, S. G., *Biochemistry* **1996**, *35*, 15057-15064.

(17) Garvey, E. P.; Lowen, G. T.; Almond, M. R., *Biochemistry* **1998**, *37*, 9043-9051.

(18) Matulic-Adamic, J.; Haerberli, P.; Usman, N., *J. Org. Chem.* **1995**, *60*, 2563-2569.

(19) (a) Zhang, J.; Lambert, E.; Xu, Z.-F.; Brioché, J.; Remy, P.; Piettre, S. R., *J. Org. Chem.* **2019**, *84*, 5245-5260; (b) Pfund, E.; Dupouy, C.; Rouanet, S.; Legay, R.; Lebarry, C.; Vasseur, J.-J.;

REFERENCES

- (1) Westheimer, F. H., *Science* **1987**, *235*, 1173-1178.
- (2) (a) Blackburn, G. M.; Brown, D.; Martin, S. J.; Parratt, M. J., *J. Chem. Soc. Perkin 1* **1987**, 181-186; (b) Blackburn, G. M.; Taylor, G. E.; Tattershall, R. H.; Thatcher, G. R. J.; McLennan, A., *Bioactive Molecules* **1987**, *3*, 451-464; (c) Blackburn, G. M.; Parratt, M. J., *J. Chem. Soc. Perkin 1* **1986**, 1417-1424;
- (3) McKenna, C. E.; Shen, P.-D., *J. Org. Chem.* **1981**, *46*, 4573-4576.
- (4) (a) Meanwell, N. A., *J. Med. Chem.* **2018**, *61*, 5822-5880; (b) Panigrahi, K.; Nelson, D. L.; Berkowitz, D. B., *Chem. Biol.* **2012**, *19*, 666-667.
- (5) Rodriguez, J. B.; Gallo-Rodriguez, C., *ChemMedChem* **2019**, *14*, 190-216.
- (6) Hoffmann, W.; Langenhan, J.; Huhmann, S.; Moschner, J.; Chang, R.; Accorsi, M.; Seo, J.; Rademann, J.; Meijer, G.; Koksche, B.; Bowers, M. T.; von Helden, G.; Pagel, K., *Angew. Chem., Int. Ed.* **2019**, *58*, 8216-8220.
- (7) (a) Halazy, S.; Ehrhard, A.; Danzin, C., *J. Am. Chem. Soc.* **1991**, *113*, 315-317; b Halazy, S.; Eggenspieler, A.; Ehrhard, A.; Danzin, C., *Bioorg. Med. Chem. Lett.* **1992**, *2*, 407-410.
- (8) Phillion, D. P.; Cleary, D. G., *J. Org. Chem.* **1992**, *57*, 2763-2764.
- (9) (a) Oertell, K.; Florian, J.; Haratipour, P.; Crans, D. C.; Kashemirov, B. A.; Wilson, S. H.; McKenna, C. E.; Goodman, M. F., *Biochemistry* **2019**, *58*, 1764-1773; (b) Haratipour, P.; Minard, C.; Nakhjiri, M.; Negahbani, A.; Kashemirov, B. A.; McKenna, C. E., *Phosphorus, Sulfur Silicon Relat. Elem.* **2019**, *194*, 329-330; (c) Oertell, K.; Kashemirov, B. A.; Negahbani, A.; Minard, C.; Haratipour, P.; Alnajjar, K. S.; Sweasy, J. B.; Batra, V. K.; Beard, W. A.; Wilson, S. H.; McKenna, C. E.; Goodman, M. F., *Biochemistry* **2018**, *57*, 3925-3933.

- Lequeux, T., *Org. Lett.* **2019**, *21*, 4803-4807; (c) Arangundy-Franklin, S.; Taylor, A. I.; Porebski, B. T.; Genna, V.; Peak-Chew, S.; Vaisman, A.; Woodgate, R.; Orozco, M.; Holliger, P., *Nat. Chem.* **2019**, *11*, 533-542; (d) Liu, C.; Cozens, C.; Jaziri, F.; Rozenski, J.; Marechal, A.; Dumbre, S.; Pezo, V.; Marliere, P.; Pinheiro, V. B.; Groaz, E.; Herdewijn, P., *J. Am. Chem. Soc.* **2018**, *140*, 6690-6699; (e) Pomeisl, K.; Beier, P.; Pohl, R.; Krecmerova, M., *ChemistrySelect* **2016**, *1*, 2102-2106; (f) Prakash, T. P.; Lima, W. F.; Murray, H. M.; Li, W.; Kinberger, G. A.; Chappell, A. E.; Gaus, H.; Seth, P. P.; Bhat, B.; Crooke, S. T.; Swayze, E. E., *Nucleic Acids Res.* **2015**, *43*, 2993-3011; (g) Shen, G. H.; Hong, J. H., *Nucleosides, Nucleotides Nucleic Acids* **2014**, *33*, 1-17.
- (20) (a) Bartee, D.; Wheadon, M. J.; Freel Meyers, C. L., *J. Org. Chem.* **2018**, *83*, 9580-9591; (b) Cocaud, C.; Nicolas, C.; Poisson, T.; Pannecoucke, X.; Legault, C. Y.; Martin, O. R., *J. Org. Chem.* **2017**, *82*, 2753-2763.
- (21) Forget, S. M.; Bhattasali, D.; Hart, V. C.; Cameron, T. S.; Syvitski, R. T.; Jakeman, D. L., *Chem. Sci.* **2012**, *3*, 1866-1878.
- (22) Cocaud, C.; Zheng, R. B.; Lowary, T. L.; Poisson, T.; Pannecoucke, X.; Nicolas, C.; Martin, O. R., *Carbohydr. Res.* **2018**, *461*, 45-50.
- (23) Berkowitz, D. B.; Bose, M.; Pfannenstiel, T. J.; Doukov, T., *J. Org. Chem.* **2000**, *65*, 4498-4508.
- (24) Baxter, N. J.; Bowler, M. W.; Alizadeh, T.; Cliff, M. J.; Hounslow, A. M.; Wu, B.; Berkowitz, D. B.; Williams, N. H.; Blackburn, G. M.; Waltho, J. P., *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 4555-4560.
- (25) (a) Prasad, V. P.; Wagner, S.; Keul, P.; Hermann, S.; Levkau, B.; Schaeffers, M.; Haufe, G., *Bioorg. Med. Chem.* **2014**, *22*, 5168-5181; (b) Nikitopoulou, I.; Kaffé, E.; Sevastou, I.; Siriti, I.; Samiotaki, M.; Madan, D.; Prestwich, G. D.; Aidinis, V., *PLoS One* **2013**, *8*, e70941; (c) Jiang, G.; Xu, Y.; Fujiwara, Y.; Tsukahara, T.; Tsukahara, R.; Gajewiak, J.; Tigyi, G.; Prestwich, G. D., *ChemMedChem* **2007**, *2*, 679-690; (d) Zhang, H.; Xu, Y.; Zhang, Z.; Liman, E. R.; Prestwich, G. D., *J. Am. Chem. Soc.* **2006**, *128*, 5642-5643; (e) Zhang, H.; Tsukahara, R.; Tigyi, G.; Prestwich, G. D., *J. Org. Chem.* **2006**, *71*, 6061-6066; (f) Xu, Y.; Lee, S. A.; Kutateladze, T. G.; Sbrissa, D.; Shisheva, A.; Prestwich, G. D., *J. Am. Chem. Soc.* **2006**, *128*, 885-897; (g) Xu, Y.; Aoki, J.; Shimizu, K.; Umezū-Goto, M.; Hama, K.; Takanezawa, Y.; Yu, S.; Mills, G. B.; Arai, H.; Qian, L.; Prestwich, G. D., *J. Med. Chem.* **2005**, *48*, 3319-3327.
- (26) Xu, Y.; Prestwich, G. D., *Org. Lett.* **2002**, *4*, 4021-4024.
- (27) (a) Berkowitz, D. B.; Sloss, D. G., *J. Org. Chem.* **1995**, *60*, 7047-50; (b) Shen, Q. R.; Sloss, D. G.; Berkowitz, D. B., *Synth. Commun.* **1994**, *24*, 1519-1530; (c) Berkowitz, D. B.; Shen, Q. R.; Maeng, J. H., *Tetrahedron Lett.* **1994**, *35*, 6445-6448; (d) Berkowitz, D. B.; Eggen, M.; Shen, Q.; Sloss, D. G., *J. Org. Chem.* **1993**, *58*, 6174-6176.
- (28) (a) Panigrahi, K.; Applegate, G. A.; Malik, G.; Berkowitz, D. B., *J. Am. Chem. Soc.* **2015**, *137*, 3600-3609; (b) Martin, S. F.; Dean, D. W.; Wagman, A. S., *Tetrahedron Lett.* **1992**, *33*, 1839-1842.
- (29) Lequeux, T. P.; Percy, J. M., *J. C. S., Chem. Commun.* **1995**, 2111-2112.
- (30) Yang, Z. Y.; Burton, D. J., *J. Org. Chem.* **1992**, *57*, 4676-4683.
- (31) Lequeux, T. P.; Percy, J. M., *Synlett* **1995**, 361-362.
- (32) (a) Yin, G.; Zhu, M.; Yang, G.; Wang, X.; Fu, W., *J. Fluorine Chem.* **2016**, *191*, 63-69; (b) Xia, X.-F.; Zhu, S.-L.; Li, Y.; Wang, H., *RSC Adv.* **2016**, *6*, 51703-51709; (c) Zhu, M.; Fu, W.; Zou, G.; Xu, C.; Wang, Z., *J. Fluorine Chem.* **2015**, *180*, 1-6; (d) De Schutter, C.; Pfund, E.; Lequeux, T., *Tetrahedron* **2013**, *69*, 5920-5926; (e) Lequeux, T.; Lebouc, F.; Lopin, C.; Yang, H.; Gouhier, G.; Piettre, S. R., *Org. Lett.* **2001**, *3*, 185-188.
- (33) (a) Singardar, M.; Mondal, S.; Laru, S.; Hajra, A., *Org. Lett.* **2019**, *21*, 5606-5610; (b) Liu, D.; Jiao, M.-J.; Wang, X.-Z.; Xu, P.-F., *Org. Lett.* **2019**, *21*, 4745-4749.
- (34) Lebargy, C.; De Schutter, C.; Legay, R.; Pfund, E.; Lequeux, T., *Synlett* **2018**, *29*, 46-50.
- (35) Kamber, M.; Just, G., *Can. J. Chem.* **1985**, *63*, 823-827.
- (36) (a) McKenna, C. E.; Schmidhauser, J., *J. C. S., Chem. Commun.* **1979**, 739; (b) McKenna, C. E.; Higa, M. T.; Cheung, N. H.; McKenna, M. C., *Tetrahedron Lett.* **1977**, 155-158.
- (37) Rabinowitz, R., *J. Org. Chem.* **1963**, *28*, 2975-2978.
- (38) Ho, T.-L.; Olah, G. A., *Angew. Chem.* **1976**, *88*, 847.
- (39) Jung, M. F.; Lyster, M. A., *J. Am. Chem. Soc.* **1977**, *99*, 968-969.
- (40) Blackburn, G. M.; Ingleson, D., *J. C. S., Chem. Commun.* **1978**, 870-871.
- (41) Hata, T.; Yamada, K.; Futatsugi, T.; Sekine, M., *Synthesis* **1979**, 189-191.
- (42) (a) Piettre, S. R.; Raboisson, P., *Tetrahedron Lett.* **1996**, *37*, 2229-2232; (b) Gordeev, M. F.; Patel, D. V.; Barker, P. L.; Gordon, E. M., *Tetrahedron Lett.* **1994**, *35*, 7585-7588; (c) Wang, M. F.; Crilley, M. M. L.; Golding, B. T.; McNally, T.; Robinson, D. H.; Tinker, A., *J. C. S., Chem. Commun.* **1991**, 667-668.
- (43) Berkowitz, D. B.; Bhuniya, D.; Peris, G., *Tetrahedron Lett.* **1999**, *40*, 1869-1872.
- (44) Barton, D. H. R.; McCombie, S. W., *J. Chem. Soc. Perkin I* **1975**, 1574-1585.
- (45) Barton, D. H. R.; Jaszberenyi, J. C., *Tetrahedron Lett.* **1989**, *30*, 2619-2622.
- (46) (a) Tanaka, S.; Kitamura, M., *e-EROS Encycl. Reagents Org. Synth.* **2010**, 1-3; (b) Tanaka, S.; Saburi, H.; Murase, T.; Ishibashi, Y.; Kitamura, M., *J. Organomet. Chem.* **2007**, *692*, 295-298; (c) Tanaka, S.; Saburi, H.; Kitamura, M., *Adv. Synth. Catal.* **2006**, *348*, 375-378; (d) Tanaka, S.; Saburi, H.; Ishibashi, Y.; Kitamura, M., *Org. Lett.* **2004**, *6*, 1873-1875.
- (47) Fux, A.; Pfanzelt, M.; Kirsch, V. C.; Hoegl, A.; Sieber, S. A., *Cell Chem. Biol.* **2019**, *26*, 1461-1468 e7.
- (48) (a) Barragan-Montero, V.; Awwad, A.; Combemale, S.; de Santa Barbara, P.; Jover, B.; Moles, J.-P.; Montero, J.-L., *ChemMedChem* **2011**, *6*, 1771-1774; (b) Clavel, C.; Barragan-Montero, V.; Garric, X.; Moles, J.-P.; Montero, J.-L., *Farmaco* **2005**, *60*, 721-725; (c) Khanjin, N. A.; Montero, J.-L., *Tetrahedron Lett.* **2002**, *43*, 4017-4020; (d) Barragan, V.; Menger, F. M.; Caran, K. L.; Vidil, C.; Moreire, A.; Montero, J.-L., *Chem. Commun.* **2001**, 85-86.
- (49) (a) Fei, X.; Zavorka, M. E.; Malik, G.; Connelly, C. M.; MacDonald, R. G.; Berkowitz, D. B., *Org. Lett.* **2017**, *19*, 4267-4270; (b) Fei, X.; Connelly, C. M.; MacDonald, R. G.; Berkowitz, D. B., *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3085-3089; (c) Berkowitz, D. B.; Maiti, G.; Charette, B. D.; Dreis, C. D.; MacDonald, R. G., *Org. Lett.* **2004**, *6*, 4921-4924.
- (50) (a) Kobzar, O. L.; Shevchuk, M. V.; Lyashenko, A. N.; Tanchuk, V. Y.; Romanenko, V. D.; Kobelev, S. M.; Averin, A. D.; Beletskaya, I. P.; Vovk, A. I.; Kukhar, V. P., *Org. Biomol. Chem.* **2015**, *13*, 7437-7444; (b) Zhang, S.; Zhang, Z.-Y., *Drug Discovery Today* **2007**, *12*, 373-381; (c) Nichols, A. J.; Mashal, R. D.; Balkan, B., *Drug Dev. Res.* **2006**, *67*, 559-566; (d) Shen, K.; Keng, Y.-F.; Wu, L.; Guo, X.-L.; Lawrence, D. S.; Zhang, Z.-Y., *J. Biol. Chem.* **2001**, *276*, 47311-47319.
- (51) Moretto, A. F.; Kirincich, S. J.; Xu, W. X.; Smith, M. J.; Wan, Z. K.; Wilson, D. P.; Follows, B. C.; Binnun, E.; Joseph-McCarthy, D.; Foreman, K.; Erbe, D. V.; Zhang, Y. L.; Tam, S. K.; Tam, S. Y.; Lee, J., *Bioorg. Med. Chem.* **2006**, *14*, 2162-2177.
- (52) Trott, O.; Olson, A. J., *J. Comput. Chem.* **2010**, *31*, 455-461.